

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the approximate reduction in the risk of disease progression or death with datopotamab deruxtecan (Dato-DXd) compared to investigator's choice of chemotherapy for patients with previously treated HR-positive, HER2-negative breast cancer in the Phase III TROPION-Breast01 study?
 - a. 2%
 - b. 37%**
 - c. 68%
2. The Phase III ASCENT-04 trial demonstrated a statistically significant progression-free survival (PFS) benefit in which of the following settings?
 - a. PD-L1-negative metastatic triple-negative breast cancer (mTNBC) after 2 prior lines of therapy
 - b. Previously untreated PD-L1-positive mTNBC**
 - c. Previously treated ESR1-mutated HR-positive metastatic breast cancer (mBC)
 - d. Previously untreated HR-positive, HER2-positive mBC
3. Adjuvant olaparib was associated with improvement in which of the following endpoints for patients with HER2-negative localized breast cancer and a BRCA germline mutation in the Phase III OlympiA trial?
 - a. Invasive disease-free survival (iDFS)
 - b. Distant disease-free survival (DDFS)
 - c. Overall survival
 - d. All of the above**
 - e. iDFS and DDFS only
4. What was the approximate objective response rate observed with neratinib for patients with HER2-mutant mTNBC in the Phase II SUMMIT trial?
 - a. 10%
 - b. 25%
 - c. 40%**
 - d. Higher than 60%
5. What was the approximate median PFS reported with Dato-DXd in the Phase III TROPION-Breast01 study for patients with HR-positive, HER2-negative advanced breast cancer?
 - a. 3.4 months
 - b. 6.9 months**
 - c. 10.7 months
 - d. 15.4 months